Key result
Aberrant cardiac RyR2 calcium release drives arrhythmias, highlighting targeted channels as key therapeutic options.
This review provides a comprehensive overview of RyR2 regulation and its role in arrhythmias, highlighting potential therapeutic targets for rebalancing calcium handling.
Calcium release through the cardiac RyR2 (type-2 ryanodine receptor) is essential for cardiac contraction. RyR2 dysfunction is associated with a spectrum of cardiac pathologies, most notably arrhythmias. While excessive RyR2 activity was historically seen as the driver of arrhythmia, it is now clear that inadequate calcium release is equally detrimental. This homeostatic balance of activity requires precise tuning, which is provided by a swathe of regulating factors spanning posttranslational modifications, protein-protein interactions, and the more recently identified positioning of individual RyR2 channels within the cell. This review summarizes how too much, or too little, calcium release can lead to arrhythmia and explores how the multitude of regulating factors work synergistically to set and modify RyR2 physiologically and become impaired in disease. Finally, we examine how RyR2-targeted pharmacological approaches can therapeutically rebalance calcium handling and inhibit arrhythmia.
No takes yet. Share an insight, caveat, or question.
Gonano et al. (2025) conducted a review in Cardiac arrhythmias and RyR2 dysfunction. RyR2-targeted pharmacological approaches was evaluated. This review highlights that both excessive and inadequate calcium release through the cardiac RyR2 channel can drive arrhythmias, and explores RyR2-targeted pharmacological approaches for treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: